Ever since the association between cancer and thrombosis was reported in
the early 19th century multiple studies have confirmed the relationship between cancer
and thrombosis. Cancer patients, especially in the first few months after diagnosis and
those with distant metastasis, have an elevated risk for VTE, and conversely, the risk of
cancer diagnosis is high within the first 2 years of idiopathic VTE. VTE has an
important impact on the prognosis of cancer patients. Thrombosis was the second
leading cause of death (9.2%) after the cancer progression (70.9%) itself. The risks of
recurrent VTE and bleeding are higher in patients with cancer-associated venous
thrombosis than patients with venous thrombosis but without cancer.
Keywords: Anticoagulants, Cancer-associated thrombosis, Cancer costs, Cancer
treatment, Coagulation in cancer, Hypercoagulability, Idiopathic VTE,
Malignancy, Pulmonary embolism, Risks for VTE, Thrombosis, Trousseau
syndrome, Venous thromboembolism, VTE prophylaxis, VTE treatment.
